SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
453.60    3.80 (0.84%)
Bid:
452.90
Ask:
453.20
Spread: 0.30 (0.066%)
Market Cap: £11.41b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Stabilisation Notice

27 Sep 2013 13:28

RNS Number : 1313P
Merrill Lynch Intl (DTG) Syndicate
27 September 2013
Β 

ο»Ώ

Β 

PRE-STABILISATION ANNOUNCEMENT

Β 

27 September 2013

Merrill Lynch Intl Syndicate

Β 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Β 

Rentokil Initial Plc

Stabilisation Notice

Β 

Merrill Lynch International (contact: Carina Powolozky telephone: 0044 207 9953966) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

Β 

The securities:

Issuer:

Rentokil Initial Plc

Guarantor (if any):

Rentokil Initial 1927 Plc

Aggregate nominal amount:

EUR 350,000,000

Description:

Senior unsecured notes

Other offer terms:

Stabilisation:

Stabilisation Manager(s):

Merrill Lynch International (Stabilisation Coordinator)Barclays Bank Plc

BNP Paribas

Mizuho International Plc

Stabilisation period expected to start on:

27 September 2013

Stabilisation period expected to end no later than:

27 October 2013 (30 days after the proposed issue date of the securities)

Existence, maximum size and conditions of use of over-allotment facility:

The Stabilisation Manager(s) may over-allot the securities to the extent permitted in accordance with applicable law.

Β 

In connection with the offer of the above securities, the Stabilisation Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilisation Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time. Any stabilisation action or over-allotment shall be conducted in accordance with all applicable laws and rules.

Β 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

Β 

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

Β 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

Β 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

Β 

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
STAPGUPPBUPWGPM
Date   Source Headline
29th Aug 20187:00 amRNSDirector/PDMR Shareholding
20th Aug 201812:44 pmRNSDirector/PDMR Shareholding
1st Aug 20183:12 pmRNSHolding(s) in Company
31st Jul 20187:00 amRNSInterim Results
27th Jul 20185:07 pmRNSHolding(s) in Company
5th Jul 20184:52 pmRNSHolding(s) in Company
5th Jul 201811:36 amRNSDirector Declaration
28th Jun 20184:10 pmRNSHolding(s) in Company
7th Jun 20185:16 pmRNSDirector Declaration
17th May 20184:12 pmRNSDirector/PDMR Shareholding
16th May 20187:00 amRNSNotice of Capital Markets Days
9th May 20185:40 pmRNSResult of AGM
4th May 20184:27 pmRNSDirector/PDMR Shareholding
2nd May 201810:52 amRNSDirector/PDMR Shareholding
1st May 20186:00 pmRNSDirector/PDMR Shareholding
30th Apr 20185:48 pmRNSDirector/PDMR Shareholding
26th Apr 20183:24 pmRNSHolding(s) in Company
25th Apr 20184:50 pmRNSHolding(s) in Company
24th Apr 20183:55 pmRNSHolding(s) in Company
24th Apr 201810:53 amRNSHolding(s) in Company
20th Apr 20184:09 pmRNSDirector/PDMR Shareholding
19th Apr 20184:32 pmRNSHolding(s) in Company
19th Apr 20187:00 amRNSQ1 Trading Update
5th Apr 201812:57 pmRNSHolding(s) in Company
5th Apr 201811:06 amRNSAnnual Financial Report
4th Apr 20186:01 pmRNSDirector/PDMR Shareholding
3rd Apr 20184:12 pmRNSBlock listing Interim Review
29th Mar 201811:55 amRNSTotal Voting Rights
27th Mar 20184:01 pmRNSHolding(s) in Company
27th Mar 201812:58 pmRNSAdditional Listing
8th Mar 20185:50 pmRNSDirector/PDMR Shareholding
1st Mar 20187:00 amRNSFinal Results
27th Dec 20177:00 amRNSDirector/PDMR Shareholding
20th Dec 20173:40 pmRNSDirector/PDMR Shareholding
22nd Nov 20174:30 pmRNSHolding(s) in Company
17th Nov 20177:00 amRNSIssue of new EUR400m bond
13th Nov 20174:35 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSPurchase of Vector Disease Acquisition LLC
7th Nov 20174:14 pmRNSHolding(s) in Company
6th Nov 20177:00 amRNSDirectorate Change
2nd Nov 20176:07 pmRNSHolding(s) in Company
1st Nov 20177:00 amRNSDirectorate Change
19th Oct 20177:00 amRNSQ3 Trading Update
2nd Oct 20173:26 pmRNSBlock listing Interim Review
21st Sep 20177:00 amRNSDirectorate Change
18th Sep 20177:00 amRNSDirectorate Change
22nd Aug 20173:34 pmRNSChange to Director's details
4th Aug 201711:57 amRNSDirector/PDMR Shareholding
31st Jul 20172:16 pmRNSDirector Declaration
27th Jul 20177:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.